Facioscapulohumeral Muscular Dystrophy - Pipeline Insight, 2025

DelveInsight's, "Facioscapulohumeral Muscular Dystrophy - Pipeline Insight, 2025" report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Facioscapulohumeral Muscular Dystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Facioscapulohumeral Muscular Dystrophy: Understanding

Facioscapulohumeral Muscular Dystrophy: Overview

Facioscapulohumeral muscular dystrophy (FSHD) is a genetic illness inherited in an autosomal dominant fashion that affects skeletal muscle tissue in affected individuals. Muscle groups involved include those of the face, shoulder girdle, and lower extremity affected asymmetrically. FSHD characteristically starts proximally in the face and spreads distally to affected muscle groups. Beyond musculature, 50% of FSHD patients also present with subclinical high-frequency hearing loss and retinovasculopathy. Symptoms typically begin in adolescence or early adulthood, and the rate of progression can vary significantly among individuals. Over time, patients may develop scapular winging, foot drop, or difficulty with activities involving facial expression, such as whistling or closing the eyes tightly.

Facioscapulohumeral Muscular Dystrophy (FSHD) typically presents with progressive muscle weakness and wasting, most notably affecting the facial muscles, shoulder girdle, upper arms, and lower legs. One hallmark of FSHD is its asymmetric involvement, where one side of the body is more affected than the other. Common signs include difficulty closing the eyes, smiling, or whistling due to facial weakness; scapular winging from shoulder muscle atrophy; and arm weakness that impairs overhead activities. Lower leg involvement may lead to foot drop, increasing the risk of tripping or falls. Additional symptoms can include abdominal muscle weakness, leading to a protruding abdomen and hyperlordosis, as well as hearing loss and, in rare cases, breathing difficulties.

The pathophysiology of Facioscapulohumeral Muscular Dystrophy (FSHD) is primarily linked to the inappropriate expression of the DUX4 gene, a double homeobox transcription factor that is normally repressed in somatic tissue. In FSHD1, a contraction of the D4Z4 macrosatellite repeat array on chromosome 4q35 reduces epigenetic repression, allowing aberrant DUX4 expression in skeletal muscle. FSHD2, though not involving a D4Z4 contraction, results from mutations in genes such as SMCHD1 or DNMT3B, which also impair epigenetic silencing of DUX4. Once expressed, DUX4 activates a cascade of cytotoxic and inflammatory gene pathways, leading to oxidative stress, impaired muscle regeneration, and ultimately progressive muscle fiber degeneration. The disease's selective muscle involvement and asymmetric distribution remain areas of active investigation.

There are currently no disease-modifying treatments for Facioscapulohumeral Muscular Dystrophy (FSHD), so management primarily focuses on supportive care. Physical therapy and rehabilitation exercises, particularly combined aerobic and strength training programs, have been shown to improve muscle function without exacerbating damage. In more advanced cases, assistive devices such as ankle-foot orthoses may help address functional limitations like foot drop. Surgical scapular fixation may alleviate severe scapular winging and improve mobility and pain, although more research is needed to validate its effectiveness. Pain and fatigue management, often involving analgesics and antidepressants, is crucial to enhancing the quality of life for patients.

"Facioscapulohumeral Muscular Dystrophy- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Facioscapulohumeral Muscular Dystrophy pipeline landscape is provided which includes the disease overview and Facioscapulohumeral Muscular Dystrophy treatment guidelines. The assessment part of the report embraces, in depth Facioscapulohumeral Muscular Dystrophy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Facioscapulohumeral Muscular Dystrophy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Facioscapulohumeral Muscular Dystrophy R&D. The therapies under development are focused on novel approaches to treat/improve Facioscapulohumeral Muscular Dystrophy.

Facioscapulohumeral Muscular Dystrophy Emerging Drugs Chapters

This segment of the Facioscapulohumeral Muscular Dystrophy report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Facioscapulohumeral Muscular Dystrophy Emerging Drugs

• AOC-1020: Avidity Biosciences, Inc.

AOC 1020 is designed to treat the underlying cause of FSHD, which is caused by the abnormal expression of a gene called double homeobox 4 or DUX4. The abnormal expression of DUX4 protein leads to changes in gene expression in muscle cells that are associated with the life-long, progressive loss of muscle function in patients with FSHD. AOC 1020 aims to reduce the expression of DUX4 mRNA and DUX4 protein in muscles in patients with FSHD. AOC 1020 consists of a proprietary monoclonal antibody that binds to the transferrin receptor 1 (TfR1) conjugated with a siRNA targeting DUX4 mRNA. In preclinical studies, a single intravenous dose with the murine version of AOC 1020 prevented development of muscle weakness demonstrated by three functional assays - treadmill running, in vivo force and compound muscle action potential. Currently, the drug is in Phase III stage of its development for the treatment of Facioscapulohumeral Muscular Dystrophy.

• RO7204239: Hoffmann-La Roche

Anti-latent myostatin (gym 329, RG6237) is a Sequential Monoclonal Antibody Recycling Technology - Immunoglobulin (SMART-Ig) using recycling and sweeping antibody technologies that eliminates latent myostatin from plasma and tissues. Latent myostatin is an inactive form that is mainly secreted from muscle cells, and is activated by BMP-1 and other protein degrading enzymes. Activated myostatin inhibits muscle growth and hypertrophy, and by inhibiting latent myostatin, gym 329 is more targeted and expected to improve the various conditions associated with muscle atrophy and loss of muscular strength. Currently, the drug is in Phase II stage of its development for the treatment of Facioscapulohumeral Muscular Dystrophy.

• ARO-DUX4: Arrowhead Pharmaceuticals

ARO-DUX4 is an RNA interference (RNAi) conjugate designed to specifically target the gene that encodes human double homeobox 4 (DUX4) protein as a potential treatment for patients with facioscapulohumeral muscular dystrophy type 1 (FSHD1). FSHD1 is an autosomal dominant disease associated with the failure to maintain complete epigenetic suppression of DUX4 expression in differentiated skeletal muscle, leading to overexpression of DUX4, which is myotoxic and can lead to muscle degeneration. Published literature suggests that the silencing of aberrantly transcribed DUX4 mRNA using ARO-DUX4 may halt progression of, and possibly reverse, DUX4-induced muscle toxicities in patients with FSHD1, improving muscle strength and function. Currently, the drug is in Phase I/II stage of its development for the treatment of Facioscapulohumeral Muscular Dystrophy.

Facioscapulohumeral Muscular Dystrophy: Therapeutic Assessment

This segment of the report provides insights about the different Facioscapulohumeral Muscular Dystrophy drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Facioscapulohumeral Muscular Dystrophy
• There are approx. 10+ key companies which are developing the therapies for Facioscapulohumeral Muscular Dystrophy. The companies which have their Facioscapulohumeral Muscular Dystrophy drug candidates in the most advanced stage, i.e. Phase III include, Avidity Biosciences, Inc.
• Phases

DelveInsight's report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Facioscapulohumeral Muscular Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Facioscapulohumeral Muscular Dystrophy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Facioscapulohumeral Muscular Dystrophy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Facioscapulohumeral Muscular Dystrophy drugs.

Facioscapulohumeral Muscular Dystrophy Report Insights

• Facioscapulohumeral Muscular Dystrophy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Facioscapulohumeral Muscular Dystrophy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Facioscapulohumeral Muscular Dystrophy drugs?
• How many Facioscapulohumeral Muscular Dystrophy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Facioscapulohumeral Muscular Dystrophy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Facioscapulohumeral Muscular Dystrophy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Facioscapulohumeral Muscular Dystrophy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Avidity Biosciences, Inc.
• Hoffmann-La Roche
• Arrowhead Pharmaceuticals
• Epicrispr Biotechnologies, Inc.
• Dyne Therapeutics, Inc.

Key Products

• AOC-1020
• RO7204239
• ARO-DUX4 for Injection
• EPI-321
• DYNE-302